Business Context and Reporting Period
This Form 10-Q covers Illumina, Inc. for the quarterly period ended June 30, 2024 (Q2 2024). The reporting period is defined by a major corporate event: the completion of the Spin-Off of GRAIL, Inc. on June 24, 2024. Illumina distributed approximately 85.5% of GRAIL's common stock to its shareholders and retained a 14.5% interest. The filing notes that the disposition did not qualify as a discontinued operation, meaning GRAIL's results remain consolidated in the financial statements for the period.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenue | $1,112 million | $1,176 million | $2,188 million | $2,263 million |
| Gross Profit | $721 million | $732 million | $1,388 million | $1,386 million |
| Gross Margin | 64.8% | 62.2% | 63.5% | 61.3% |
| Operating Loss | $(1,637) million | $(88) million | $(1,749) million | $(152) million |
| Net Loss | $(1,988) million | $(234) million | $(2,114) million | $(231) million |
| Diluted EPS | $(12.48) | $(1.48) | $(13.28) | $(1.46) |
| Cash & Equivalents | $920 million | $1,048 million (Dec 31, 2023) | N/A | |
| Short-term Investments | $74 million | $6 million (Dec 31, 2023) | N/A | |
| Total Debt (Current + Non-current) | $2,234 million | $1,489 million (Dec 31, 2023) | N/A | |
| Operating Cash Flow (YTD) | $157 million | $115 million | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 5% in Q2 2024 and 3% YTD 2024 compared to the prior year. This was primarily driven by a 39% drop in sequencing instrument revenue due to fewer shipments of high-throughput instruments and capital constraints among customers.
- Significant Impairment Charges: The company recorded a non-cash goodwill and intangible impairment charge of $1,886 million in Q2 2024 ($1,889 million YTD). This consisted of a $1,466 million goodwill impairment and a $420 million in-process research and development (IPR&D) impairment related to the GRAIL reporting unit, triggered by the Spin-Off valuation.
- Investment Losses: Following the Spin-Off, Illumina recorded an unrealized loss of $328 million on its retained 14.5% investment in GRAIL, classified under "Other (expense) income, net."
- Debt Structure: To fund the GRAIL Spin-Off, Illumina borrowed $750 million under a new 364-day Delayed Draw Term Loan in June 2024. Total term debt increased from $1,489 million at year-end 2023 to $2,234 million.
- SG&A Volatility: Selling, general, and administrative expenses decreased significantly year-over-year ($315 million in Q2) largely due to a $271 million gain on the change in fair value of contingent consideration liabilities (CVRs) related to GRAIL, offset by $37 million in Spin-Off transaction costs.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects continued impact from macroeconomic factors, including inflation and customer inventory management. The company is focusing on cost reduction initiatives to improve margins.
- European Commission Fine: A significant contingent liability exists regarding a €432 million fine imposed by the European Commission in July 2023 for breaching the EU Merger Regulation. As of June 30, 2024, Illumina has accrued $481 million (including interest and FX fluctuations) for this fine. The company is appealing the decision.
- Legal Proceedings: The filing details extensive ongoing litigation, including FTC administrative complaints, EU General Court appeals regarding jurisdiction, multiple shareholder derivative suits, and securities class actions related to the GRAIL acquisition.
- Regulatory Risk (FDA): The FDA issued a Final Rule in April 2024 regarding Laboratory Developed Tests (LDTs). While most of Illumina's current LDT revenue falls outside the immediate scope, future regulatory clearance requirements for new products could impact operations.
- Unusual Items: The Q2 results are heavily distorted by the one-time $1.889 billion impairment charge and the $328 million unrealized loss on the GRAIL investment, which are non-recurring events tied to the Spin-Off.
Investor Verification Checklist
- Impairment Methodology: Verify the assumptions used in the discounted cash flow models for the GRAIL goodwill and IPR&D impairments, specifically the discount rates and revenue forecasts.
- European Commission Appeal Status: Monitor the progress of the appeal against the €432 million fine and the jurisdictional challenge, as a loss could require immediate cash payment.
- GRAIL Investment Valuation: Track the fair value of the retained 14.5% GRAIL stake, which is subject to significant volatility and unrealized losses.
- Debt Maturity Profile: Note the $750 million Delayed Draw Term Loan matures in June 2025; assess the company's ability to refinance or repay this obligation.
- Core Illumina Performance: Isolate the performance of the "Core Illumina" segment (excluding GRAIL) to understand the underlying operational health of the sequencing business, which reported an operating income of $442 million in Q2 2024.